A first-in-man phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody OMP-305B83 in patients with previously treated solid tumors. (December 2016) - Jimeno, A.; Moore, K.; Gordon, M.; Chugh, R.; Diamond, J.; Aljumaily, R.; Stagg, R.; Dupont, J.; Smith, D.